WSJ US BusinessTelehealth Startup Cerebral to Stop Prescribing Adderall for New Patients

May 4, 20220

Cerebral Inc. executives told its clinicians that the company will pause prescribing controlled substances such as Adderall to treat attention-deficit hyperactivity disorder in new patients beginning Monday, the company said.

Cerebral’s co-founder and chief executive, Kyle Robertson, made the announcement in an email sent to staff on Wednesday, adding that the company will continue to treat existing ADHD patients.

To Read the Full Story

Leave a Reply

Your email address will not be published. Required fields are marked *

700 Louisiana Street , Houston TX. 77002
(+1) 832-390-2738

Follow us:


Calls may be recorded for quality and training purposes.

Copyright © GMI 2020